A roxoithromycin and compound recipe preparation

Abstract

The invention relates to compound preparation of soluble erythromycin and pidotimod, which is used for treating bacterial infectious diseases. The preparation has the composition that the soluble erythromycin is 100 to 600 mg, and the pidotimod is 200 to 1600 mg. Acceptable auxiliary materials are added according to the composition to produce pharmaceutically acceptable dosage form and to be used for clinical treatment of the bacterial infectious diseases, and simultaneously the compound preparation also has the function of immunologic function adjustment. The compound preparation has obvious synergism, the two components do not have interaction, no accumulation effect exists in a body, untoward reaction happens rarely, and the compound preparation takes effect rapidly and durably. The compound preparation is helpful for shortening the course of treatment and the probability of recurrence of a patient, can reduce the probability of the increase of the bacterial drug resistance, has wider application range, and has the dual functions of prevention and treatment.

Description

technical field [0001] The invention relates to a compound preparation of roxithromycin and pidotimod, which is used for treating bacterial infectious diseases. Background technique [0002] Since the discovery of the first macrolide drug erythromycin in 1952, it has a significant effect on penicillin-resistant Staphylococcus aureus. In recent decades, hundreds of antibiotics have been launched one after another, providing effective weapons for bacterial infectious diseases. Infectious diseases are the most common problems in clinical work, in which about 80% of infections in adults are caused by bacteria, involving outpatients and hospitalized patients. The most important means of clinical treatment of bacterial infections is the use of various antibiotics, resulting in resistance to antibiotics, and also led to problems such as complicated infections, refractory infections, and recurrent infections in the clinical treatment of such patients. At the same time, due to the ...

AI Technical Summary

Problems solved by technology

[0005] Immunological studies have shown that patients with infectious diseases generally have a low level of anti-infection immunity. Relying solely on exogenous antibacterial drugs cannot completely eliminate pathogenic bacteria, and it is easy to leave hidden dangers of inducing drug resistance. The strategy of combined treatment of infection, especially the use of appropriate immunotherapy drugs, should be the best way to treat bacterial infections by improving the patient's own anti-infection immunity and mobilizing the body's endogenous anti-infection ability

Images